FY2017 Earnings Estimate for Hologic, Inc. Issued By William Blair (HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair issued their FY2017 earnings estimates for Hologic in a research report issued to clients and investors on Thursday. William Blair analyst B. Weinstein anticipates that the medical equipment provider will earn $2.02 per share for the year.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.46 by $0.04. The firm had revenue of $715.40 million during the quarter, compared to analyst estimates of $685.24 million. Hologic had a return on equity of 27.17% and a net margin of 11.57%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.47 earnings per share.

WARNING: “FY2017 Earnings Estimate for Hologic, Inc. Issued By William Blair (HOLX)” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2017/06/16/fy2017-earnings-estimate-for-hologic-inc-issued-by-william-blair-holx-updated-updated-updated.html.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Several other research analysts have also recently weighed in on HOLX. Canaccord Genuity restated a “buy” rating and set a $53.00 target price on shares of Hologic in a report on Tuesday, May 9th. Stifel Nicolaus boosted their target price on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, May 11th. BTIG Research restated a “buy” rating and set a $47.00 target price on shares of Hologic in a report on Sunday. Leerink Swann reiterated an “outperform” rating and issued a $52.00 price objective on shares of Hologic in a report on Thursday, March 30th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $51.00 price objective on shares of Hologic in a report on Tuesday, March 14th. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $47.54.

Shares of Hologic (NASDAQ:HOLX) traded down 1.1011% on Monday, hitting $42.9617. The stock had a trading volume of 5,952,019 shares. The firm’s 50-day moving average price is $43.61 and its 200 day moving average price is $40.79. The firm has a market cap of $12.04 billion, a P/E ratio of 15.4040 and a beta of 1.10. Hologic has a 12 month low of $32.64 and a 12 month high of $46.05.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cleararc Capital Inc. boosted its position in Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 77 shares during the period. Compton Capital Management Inc. RI boosted its position in Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock worth $715,000 after buying an additional 100 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Hologic by 0.7% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,949 shares of the medical equipment provider’s stock worth $640,000 after buying an additional 104 shares during the period. Advantus Capital Management Inc boosted its position in Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock worth $1,189,000 after buying an additional 116 shares during the period. Finally, First Citizens Bank & Trust Co. boosted its position in Hologic by 1.4% in the third quarter. First Citizens Bank & Trust Co. now owns 10,559 shares of the medical equipment provider’s stock worth $410,000 after buying an additional 144 shares during the period. Institutional investors own 94.09% of the company’s stock.

In other Hologic news, Director Lawrence M. Levy sold 10,203 shares of the company’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $45.00, for a total transaction of $459,135.00. Following the transaction, the director now directly owns 38,832 shares in the company, valued at $1,747,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 9,837 shares of the company’s stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $45.34, for a total value of $446,009.58. Following the transaction, the director now owns 40,577 shares in the company, valued at $1,839,761.18. The disclosure for this sale can be found here. Insiders have sold 95,476 shares of company stock worth $4,146,707 over the last 90 days. 0.79% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply